Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025

Global Metabolic Dysfunction Associated Steatohepatitis MASH Treatment Market Report 2025

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025 – By Treatment (By Drug, By Therapy), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-User), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

Name: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025

Proud Members Of

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Definition

Metabolic dysfunction-associated steatohepatitis (MASH) treatment refers to medical and lifestyle interventions aimed at addressing inflammation and liver damage caused by fat accumulation in the liver associated with metabolic dysfunctions like obesity, diabetes, and insulin resistance, focusing on improving liver health and metabolic outcomes.

The main treatments in metabolic dysfunction-associated steatohepatitis (MASH) treatment are drug and therapy. Drug treatment refers to the use of pharmaceutical therapies aimed at reducing liver inflammation, fibrosis, and fat accumulation associated with the condition, with the goal of improving liver function and preventing disease progression. The end users of this are hospitals, specialty clinics, homecare, and others, and are distributed by various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segmentation

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented –

1) By Treatment: By Drug, By Therapy

2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, vitamin e, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)

2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size and growth rate 2025 to 2029: Graph

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size 2025 And Growth Rate

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size has grown exponentially in recent years. It will grow from $2.00 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 30.0%. The growth in the historic period can be attributed to the rising incidence of non-alcoholic steatohepatitis, modern dietary habits, eating high in processed foods, sedentary lifestyles, and increasing prevalence of metabolic.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Forecast

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size is expected to see exponential growth in the next few years. It will grow to $7.38 billion in 2029 at a compound annual growth rate (CAGR) of 29.8%. The growth in the forecast period can be attributed to the increasing prevalence of obesity and obesity-related diseases, early intervention, reimbursement mechanisms, insurance coverage, and growing awareness of liver diseases. Major trends in the forecast period include an increase in technological advancements, pipeline development, strategic collaborations and partnerships, personalized medicine and precision therapeutics, and investment in clinical trials and research.

Book your 30 minutes free consultation with our research experts

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Driver: Rising Obesity Prevalence Driving Growth In The Market

The increasing prevalence of obesity is expected to propel the growth of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact overall health, typically measured by a body mass index (BMI) of 30 or higher. The prevalence of obesity is rising globally, driven by sedentary lifestyles, unhealthy diets, and metabolic risk factors. Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment in obesity focuses on addressing insulin resistance, reducing liver fat, and improving metabolic health through lifestyle changes and targeted therapies. For instance, in March 2023, according to the World Heart Foundation, a Switzerland-based non-government global cardiovascular community, Currently, approximately 2.3 billion adults and children worldwide are obese or overweight, and with the ongoing obesity trend, this number is projected to reach 2.7 billion by 2025. Therefore, the increasing prevalence of obesity is driving growth in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Major Players

Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Trend: Innovative MASH Treatments Address Fibrosis And Improve Liver Health Outcomes

Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focusing on developing innovative products such as liver fibrosis treatment solutions to provide the treatment option for patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. Liver fibrosis treatment solutions focus on addressing the underlying causes of liver damage through lifestyle modifications, antiviral medications, and emerging antifibrotic therapies, aiming to halt or reverse the progression of fibrosis and improve liver function. For instance, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom), the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily oral tablet that demonstrated efficacy in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This breakthrough offers a non-invasive treatment alternative, eliminating the need for liver biopsies, and significantly improves patient access and outcomes in managing fatty liver disease.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Merger And Acquisition: Boehringer Ingelheim Collaborates With Ribo To Develop NASH And MASH Treatments

In January 2024, Suzhou Ribo Life Science Co., Ltd., a China-based clinical-stage company, and Ribocure Pharmaceuticals AB (Ribo), a Sweden-based clinical-stage biotechnology company, announced a collaboration with Boehringer Ingelheim for $2 billion. This partnership aims to develop innovative treatments for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) by combining Ribo’s RNAi therapeutic platform with Boehringer Ingelheim’s expertise in cardiovascular, renal, and metabolic diseases. The collaboration focuses on addressing the urgent need for effective therapies to halt NASH progression and restore liver function. Boehringer Ingelheim is a Germany-based pharmaceutical company actively involved in developing treatments for metabolic dysfunction-associated steatohepatitis (MASH).

Regional Outlook For The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market consists of revenues earned by entities by providing services such as clinical care services, nutritional counseling, pharmacotherapy management, patient education, and support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market also includes sales of antioxidants, antidiabetic drugs, and liver protective supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Industry?

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report is one of a series of new reports from The Business Research Company that provides metabolic dysfunction-associated steatohepatitis (MASH) treatment market statistics, including metabolic dysfunction-associated steatohepatitis (MASH) treatment industry global market size, regional shares, competitors with metabolic dysfunction-associated steatohepatitis (MASH) treatment market share, detailed metabolic dysfunction-associated steatohepatitis (MASH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic dysfunction-associated steatohepatitis (MASH) treatment industry. This metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	2.60 billion
Revenue Forecast In 2034	$7.38 billion
Growth Rate	CAGR of 29.8% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented – 1) By Treatment: By Drug, By Therapy 2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies Subsegments: 1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents) 2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Characteristics

3. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Trends And Strategies

4. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Rate Analysis

5.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Total Addressable Market (TAM)

6. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segmentation

6.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

By Drug

By Therapy

6.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Homecare

Other End-User

6.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

6.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antifibrotic Agents

Antidiabetic Drugs

Lipid-Lowering Agents

Vitamin E

Obeticholic Acid (OCA)

GLP-1 Agonists

Other Drugs (Anti-Inflammatory Agents)

6.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pharmacotherapy

Lifestyle Modifications (Dietary Changes, Exercise)

Bariatric Surgery

Liver Transplantation

7. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Regional And Country Analysis

7.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

8.1. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

9.1. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

9.2. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

10.1. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

11.1. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

11.2. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

12.1. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

13.1. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

14.1. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

14.2. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

15.1. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

15.2. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

16.1. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

17.1. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

18.1. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

19.1. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

20.1. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

21.1. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

21.2. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

22.1. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

23.1. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

23.2. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

24.1. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

24.2. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

25.1. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

25.2. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

26.1. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

26.2. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

27.1. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

28.1. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

28.2. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

29.1. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

29.2. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape And Company Profiles

30.1. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape

30.2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. Eli Lilly and Company

31.3. Gilead Sciences Inc.

31.4. Boehringer Ingelheim International GmbH

31.5. Novo Nordisk A/S

31.6. Apollo Health and Lifestyle Limited

31.7. Jenny Craig

31.8. Celerion

31.9. Nutrisystem

31.10. Madrigal Pharmaceuticals

31.11. Anoos Clinic

31.12. 89 Bio

31.13. Biosynth

31.14. DiogenX

31.15. Galectin Therapeutics Inc.

32. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

34. Recent Developments In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

35. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market High Potential Countries, Segments and Strategies

35.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Countries Offering Most New Opportunities

35.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Segments Offering Most New Opportunities

35.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Pfizer Inc. Financial Performance

Table 77: Johnson & Johnson Financial Performance

Table 78: Merck & Co. Inc. Financial Performance

Table 79: Sanofi SA Financial Performance

Table 80: AstraZeneca PLC Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Pfizer Inc. Financial Performance

Figure 77: Johnson & Johnson Financial Performance

Figure 78: Merck & Co. Inc. Financial Performance

Figure 79: Sanofi SA Financial Performance

Figure 80: AstraZeneca PLC Financial Performance

Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis

How Will The Nuclear Medicine Market Grow In 2022?

What Is The Pediatric Imaging Market Overview In 2022?

Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company

The Business Research Company offers the medical aesthetics market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the clinical chemistry market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rcm market research report 2022 with industry size, share, segments and market growth

Metabolic Disorders Drugs Global Market Report 2022 – By Type (Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Cardiometabolic Diseases Global Market Report 2025 – By Type (Chronic/Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity), By Treatment (ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments), By Dosage (Tablet, Injection), By Route Of Administration (Oral, Intravenous, Other Routes Of Administration ), By End-Users (Clinic, Hospital, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Comprehensive Metabolic Panel (CMP) Testing Global Market Report 2025 – By Disease (Kidney Disease, Liver Disease, Diabetes, Other Diseases), By Test Type (Proteins, Electrolytes, Kidney Tests, Liver Functional Tests, Glucose), By End User (Laboratories, Point Of Care (PoC)) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025 – By Drug Type( Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types), By Test Type( Blood Tests, Liver Biopsy, Imaging Procedures), By End User( Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025 – By Type (Solid, Liquid), By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products), By Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), By Sales Channel (Hospital Pharmacy, Retail Pharmacy, Online Provider), By Application (Oral, Parenteral) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2025 – By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types), By Disease (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), By End Use (Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Drugs For Erectile Dysfunction Global Market Report 2025 – By Drugs (Sildenafil Citrate, Mirodenafil , Vardenafil), By Mode of Administration (Oral, Topical, Injections), By End users (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Glioblastoma Multiforme (GBM) Treatment Global Market Report 2025 – By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drug Class (Temozolomide, Bevacizumab, Lostine, Carstone Wafers, Other Drug Classes), By Route of Administration (Oral, Parenteral, Other Route Of Administrations), By End-Use (Hospitals, Clinics, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market?

How will the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market drivers and restraints affect the market dynamics? What forces will shape the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment industry going forward?

The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market major growth driver - Rising Obesity Prevalence Driving Growth In The Market. For further insights on the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market request a sample here

What is the forecast market size or the forecast market value of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market?

The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market size has grown strongly in recent years. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size has grown exponentially in recent years. It will grow from $2.00 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 30.0%. The growth in the historic period can be attributed to the rising incidence of non-alcoholic steatohepatitis, modern dietary habits, eating high in processed foods, sedentary lifestyles, and increasing prevalence of metabolic. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size is expected to see exponential growth in the next few years. It will grow to $7.38 billion in 2029 at a compound annual growth rate (CAGR) of 29.8%. The growth in the forecast period can be attributed to the increasing prevalence of obesity and obesity-related diseases, early intervention, reimbursement mechanisms, insurance coverage, and growing awareness of liver diseases. Major trends in the forecast period include an increase in technological advancements, pipeline development, strategic collaborations and partnerships, personalized medicine and precision therapeutics, and investment in clinical trials and research. For further insights on the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market, request a sample here

How is the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market segmented?

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented –
1) By Treatment: By Drug, By Therapy
2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation For further insights on the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market, request a sample here

Which region has the largest share of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market? What are the other regions covered in the report?

Who are the major players in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market?

What are the key trends in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market?

Major trends in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market include Innovative MASH Treatments Address Fibrosis And Improve Liver Health Outcomes. For further insights on the Metabolic Dysfunction-Associated Steatohepatiti request a sample here.

What are the major opportunities in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market? What are the strategies for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market?

For detailed insights on the major opportunities and strategies in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market, request a sample here.

How does the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market relate to the overall economy and other similar markets?

For detailed insights on Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment industry?

For detailed insights on the mergers and acquisitions in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment industry, request a sample here.

What are the key dynamics influencing the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market growth? SWOT analysis of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market.

For detailed insights on the key dynamics influencing the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market growth and SWOT analysis of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment industry, request a sample here.